The early detection research network's specimen reference sets

Paving the way for rapid evaluation of potential biomarkers

Ziding Feng, Jacob Kagan, Margaret Pepe, Mark Thornquist, Jo Ann Rinaudo, Jackie Dahlgren, Karl Krueger, Yingye Zheng, Christos Patriotis, Ying Huang, Lynn Sorbara, Ian Thompson, Sudhir Srivastava

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

BACKGROUND: The mission of the National Cancer Institute's Early Detection Research Network (EDRN) is to identify and validate cancer biomarkers for clinical use. Since its inception, EDRN investigators have learned a great deal about the process of validating biomarkers for clinical use. Translational research requires a broad spectrum of research expertise, and coordinating collaborative activities can be challenging. The EDRN has developed a robust triage and validation system that serves the roles of both " facilitator" and "brake." CONTENT: The system consists of (a) establishing a reference set of specimens collected under PRoBE (Prospective Specimen Collection Retrospective Blinded Evaluation) design criteria; (b) using the reference set to prevalidate candidate biomarkers before committing to full-scale validation; (c) performing full-scale validation for those markers that pass prevalidation testing; and (d) ensuring that the reference set is sufficiently large in numbers and volumes of sample that it can also be used to study future candidate biomarkers. This system provides rigorous and efficient evaluation of candidate biomarkers and biomarker panels. Reference sets should also be constructed to enable high-quality biomarker-discovery research. SUMMARY: We describe the process of establishing our system in the hope that it will serve as an example of how to validate biomarkers for clinical application. We also hope that this description of the biospecimen reference sets available from the EDRN will encourage the biomarker research community-from academia or industry-to use this resource to advance biomarkers into clinical use.

Original languageEnglish (US)
Pages (from-to)68-74
Number of pages7
JournalClinical Chemistry
Volume59
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Biomarkers
Research
Specimen Handling
Translational Medical Research
National Cancer Institute (U.S.)
Triage
Tumor Biomarkers
Brakes
Industry
Research Personnel
Testing

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

The early detection research network's specimen reference sets : Paving the way for rapid evaluation of potential biomarkers. / Feng, Ziding; Kagan, Jacob; Pepe, Margaret; Thornquist, Mark; Rinaudo, Jo Ann; Dahlgren, Jackie; Krueger, Karl; Zheng, Yingye; Patriotis, Christos; Huang, Ying; Sorbara, Lynn; Thompson, Ian; Srivastava, Sudhir.

In: Clinical Chemistry, Vol. 59, No. 1, 01.2013, p. 68-74.

Research output: Contribution to journalArticle

Feng, Z, Kagan, J, Pepe, M, Thornquist, M, Rinaudo, JA, Dahlgren, J, Krueger, K, Zheng, Y, Patriotis, C, Huang, Y, Sorbara, L, Thompson, I & Srivastava, S 2013, 'The early detection research network's specimen reference sets: Paving the way for rapid evaluation of potential biomarkers', Clinical Chemistry, vol. 59, no. 1, pp. 68-74. https://doi.org/10.1373/clinchem.2012.185140
Feng, Ziding ; Kagan, Jacob ; Pepe, Margaret ; Thornquist, Mark ; Rinaudo, Jo Ann ; Dahlgren, Jackie ; Krueger, Karl ; Zheng, Yingye ; Patriotis, Christos ; Huang, Ying ; Sorbara, Lynn ; Thompson, Ian ; Srivastava, Sudhir. / The early detection research network's specimen reference sets : Paving the way for rapid evaluation of potential biomarkers. In: Clinical Chemistry. 2013 ; Vol. 59, No. 1. pp. 68-74.
@article{34730e41171f44818137c22ae7be9952,
title = "The early detection research network's specimen reference sets: Paving the way for rapid evaluation of potential biomarkers",
abstract = "BACKGROUND: The mission of the National Cancer Institute's Early Detection Research Network (EDRN) is to identify and validate cancer biomarkers for clinical use. Since its inception, EDRN investigators have learned a great deal about the process of validating biomarkers for clinical use. Translational research requires a broad spectrum of research expertise, and coordinating collaborative activities can be challenging. The EDRN has developed a robust triage and validation system that serves the roles of both {"} facilitator{"} and {"}brake.{"} CONTENT: The system consists of (a) establishing a reference set of specimens collected under PRoBE (Prospective Specimen Collection Retrospective Blinded Evaluation) design criteria; (b) using the reference set to prevalidate candidate biomarkers before committing to full-scale validation; (c) performing full-scale validation for those markers that pass prevalidation testing; and (d) ensuring that the reference set is sufficiently large in numbers and volumes of sample that it can also be used to study future candidate biomarkers. This system provides rigorous and efficient evaluation of candidate biomarkers and biomarker panels. Reference sets should also be constructed to enable high-quality biomarker-discovery research. SUMMARY: We describe the process of establishing our system in the hope that it will serve as an example of how to validate biomarkers for clinical application. We also hope that this description of the biospecimen reference sets available from the EDRN will encourage the biomarker research community-from academia or industry-to use this resource to advance biomarkers into clinical use.",
author = "Ziding Feng and Jacob Kagan and Margaret Pepe and Mark Thornquist and Rinaudo, {Jo Ann} and Jackie Dahlgren and Karl Krueger and Yingye Zheng and Christos Patriotis and Ying Huang and Lynn Sorbara and Ian Thompson and Sudhir Srivastava",
year = "2013",
month = "1",
doi = "10.1373/clinchem.2012.185140",
language = "English (US)",
volume = "59",
pages = "68--74",
journal = "Clinical Chemistry",
issn = "0009-9147",
publisher = "American Association for Clinical Chemistry Inc.",
number = "1",

}

TY - JOUR

T1 - The early detection research network's specimen reference sets

T2 - Paving the way for rapid evaluation of potential biomarkers

AU - Feng, Ziding

AU - Kagan, Jacob

AU - Pepe, Margaret

AU - Thornquist, Mark

AU - Rinaudo, Jo Ann

AU - Dahlgren, Jackie

AU - Krueger, Karl

AU - Zheng, Yingye

AU - Patriotis, Christos

AU - Huang, Ying

AU - Sorbara, Lynn

AU - Thompson, Ian

AU - Srivastava, Sudhir

PY - 2013/1

Y1 - 2013/1

N2 - BACKGROUND: The mission of the National Cancer Institute's Early Detection Research Network (EDRN) is to identify and validate cancer biomarkers for clinical use. Since its inception, EDRN investigators have learned a great deal about the process of validating biomarkers for clinical use. Translational research requires a broad spectrum of research expertise, and coordinating collaborative activities can be challenging. The EDRN has developed a robust triage and validation system that serves the roles of both " facilitator" and "brake." CONTENT: The system consists of (a) establishing a reference set of specimens collected under PRoBE (Prospective Specimen Collection Retrospective Blinded Evaluation) design criteria; (b) using the reference set to prevalidate candidate biomarkers before committing to full-scale validation; (c) performing full-scale validation for those markers that pass prevalidation testing; and (d) ensuring that the reference set is sufficiently large in numbers and volumes of sample that it can also be used to study future candidate biomarkers. This system provides rigorous and efficient evaluation of candidate biomarkers and biomarker panels. Reference sets should also be constructed to enable high-quality biomarker-discovery research. SUMMARY: We describe the process of establishing our system in the hope that it will serve as an example of how to validate biomarkers for clinical application. We also hope that this description of the biospecimen reference sets available from the EDRN will encourage the biomarker research community-from academia or industry-to use this resource to advance biomarkers into clinical use.

AB - BACKGROUND: The mission of the National Cancer Institute's Early Detection Research Network (EDRN) is to identify and validate cancer biomarkers for clinical use. Since its inception, EDRN investigators have learned a great deal about the process of validating biomarkers for clinical use. Translational research requires a broad spectrum of research expertise, and coordinating collaborative activities can be challenging. The EDRN has developed a robust triage and validation system that serves the roles of both " facilitator" and "brake." CONTENT: The system consists of (a) establishing a reference set of specimens collected under PRoBE (Prospective Specimen Collection Retrospective Blinded Evaluation) design criteria; (b) using the reference set to prevalidate candidate biomarkers before committing to full-scale validation; (c) performing full-scale validation for those markers that pass prevalidation testing; and (d) ensuring that the reference set is sufficiently large in numbers and volumes of sample that it can also be used to study future candidate biomarkers. This system provides rigorous and efficient evaluation of candidate biomarkers and biomarker panels. Reference sets should also be constructed to enable high-quality biomarker-discovery research. SUMMARY: We describe the process of establishing our system in the hope that it will serve as an example of how to validate biomarkers for clinical application. We also hope that this description of the biospecimen reference sets available from the EDRN will encourage the biomarker research community-from academia or industry-to use this resource to advance biomarkers into clinical use.

UR - http://www.scopus.com/inward/record.url?scp=84872038824&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872038824&partnerID=8YFLogxK

U2 - 10.1373/clinchem.2012.185140

DO - 10.1373/clinchem.2012.185140

M3 - Article

VL - 59

SP - 68

EP - 74

JO - Clinical Chemistry

JF - Clinical Chemistry

SN - 0009-9147

IS - 1

ER -